|
Nov 29
|
We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt
|
|
Nov 28
|
Merck Announces First-Quarter 2024 Dividend
|
|
Nov 28
|
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
|
|
Nov 10
|
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
|
|
Nov 9
|
Top Analyst Reports for McDonald's, ConocoPhillips & RTX
|
|
Nov 9
|
Deutsche warms to Merck; Ralph Lauren snags a buy rating: 4 big analyst picks
|
|
Nov 8
|
Merck to Participate in the Jefferies London Healthcare Conference
|
|
Nov 6
|
Insiders At Merck Sold US$5.5m In Stock, Alluding To Potential Weakness
|
|
Nov 4
|
3 Trustworthy Blue-Chip Stocks to Buy Now
|
|
Aug 10
|
The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake
|
|
Aug 8
|
Merck Is Harnessing Innovation To Reach Indigenous Communities
|
|
Aug 7
|
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
|